Small molecule · Inhibitor of cyclin-dependent kinase 7 (CDK7) · developed by Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals
GTAEXS617 (REC-617) is an orally bioavailable, non-covalent, reversible inhibitor of cyclin-dependent kinase 7 (CDK7). By blocking CDK7, it prevents phosphorylation of the RNA polymerase II carboxy-terminal domain and of cell cycle kinases CDK1, 2, 4 and 6. It is being studied in head and neck squamous cell carcinoma, pancreatic adenocarcinoma, non-small cell lung cancer, ovarian cancer, and breast and triple negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05985655 | Phase 1/2 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Recruiting | RXRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic AdenocarcinomaTriple Negative Breast Cancer (TNBC)
Updated Nov 1, 2026. Something wrong or missing? Report it on the RXRX page.
See RXRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RXRX catalysts and pipeline →